These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 8615651)

  • 1. Energetic characteristics of cisplatin resistant ovarian carcinoma cells.
    Dorward AM; Singh G
    Anticancer Res; 1996; 16(1):443-7. PubMed ID: 8615651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of mitochondria in cisplatin-resistant human ovarian carcinoma cells.
    Hirama M; Isonishi S; Yasuda M; Ishikawa H
    Oncol Rep; 2006 Nov; 16(5):997-1002. PubMed ID: 17016583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitochondrial defects in cis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cells.
    Andrews PA; Albright KD
    Cancer Res; 1992 Apr; 52(7):1895-901. PubMed ID: 1551118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of cis-diamminedichloroplatinum(II) resistance in human ovarian carcinoma cells selected for rhodamine 123 resistance.
    Zinkewich-Péotti K; Andrews PA
    Cancer Res; 1992 Apr; 52(7):1902-6. PubMed ID: 1551119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
    Sharp SY; Rogers PM; Kelland LR
    Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway.
    Yang X; Fraser M; Moll UM; Basak A; Tsang BK
    Cancer Res; 2006 Mar; 66(6):3126-36. PubMed ID: 16540663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Metabolic reprogramming" in ovarian cancer cells resistant to cisplatin.
    Montopoli M; Bellanda M; Lonardoni F; Ragazzi E; Dorigo P; Froldi G; Mammi S; Caparrotta L
    Curr Cancer Drug Targets; 2011 Feb; 11(2):226-35. PubMed ID: 21158717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel phosphonium salts display in vitro and in vivo cytotoxic activity against human ovarian cancer cell lines.
    Manetta A; Gamboa G; Nasseri A; Podnos YD; Emma D; Dorion G; Rawlings L; Carpenter PM; Bustamante A; Patel J; Rideout D
    Gynecol Oncol; 1996 Feb; 60(2):203-12. PubMed ID: 8631539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
    Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
    Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear and mitochondrial distribution of organoamidoplatinum(II) lesions in cisplatin-sensitive and -resistant adenocarcinoma cells.
    Talarico T; Cullinane CM; Gray PJ; Webster LK; Deacon GB; Phillips DR
    Anticancer Drug Des; 2001; 16(2-3):135-41. PubMed ID: 11962511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells.
    Marverti G; Ligabue A; Paglietti G; Corona P; Piras S; Vitale G; Guerrieri D; Luciani R; Costi MP; Frassineti C; Moruzzi MS
    Eur J Pharmacol; 2009 Aug; 615(1-3):17-26. PubMed ID: 19446547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effect of mitochondrial inhibitors on mitochondrial membrane potential in two different cell lines using flow cytometry and spectrofluorometry.
    Kalbácová M; Vrbacký M; Drahota Z; Melková Z
    Cytometry A; 2003 Apr; 52(2):110-6. PubMed ID: 12655654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells.
    Marzano C; Gandin V; Folda A; Scutari G; Bindoli A; Rigobello MP
    Free Radic Biol Med; 2007 Mar; 42(6):872-81. PubMed ID: 17320769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of the cisplatin resistance phenotype in a human ovarian carcinoma cell line segregates with chromosomes 11 and 16.
    Mirakhur B; Parekh HK; Simpkins H
    Cancer Res; 1996 May; 56(10):2256-62. PubMed ID: 8625294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiosensitivity in multidrug-resistant and cisplatin-resistant human carcinoma cell lines.
    Gigante M; Toffoli G; Bertola A; Biscontin G; Dassie A; Zanelli GD; Zanin E; Trovò MG; Muzzio PC
    Am J Clin Oncol; 2003 Aug; 26(4):e73-9. PubMed ID: 12902902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigallocatechin-3-gallate delivers hydrogen peroxide to induce death of ovarian cancer cells and enhances their cisplatin susceptibility.
    Chan MM; Soprano KJ; Weinstein K; Fong D
    J Cell Physiol; 2006 May; 207(2):389-96. PubMed ID: 16402374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. alpha-TEA inhibits survival and enhances death pathways in cisplatin sensitive and resistant human ovarian cancer cells.
    Yu W; Shun MC; Anderson K; Chen H; Sanders BG; Kline K
    Apoptosis; 2006 Oct; 11(10):1813-23. PubMed ID: 16850165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells.
    Yang X; Xing H; Gao Q; Chen G; Lu Y; Wang S; Ma D
    Gynecol Oncol; 2005 May; 97(2):413-21. PubMed ID: 15863139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in mitochondrial mass, membrane potential, and cellular adenosine triphosphate content during the cell cycle of human leukemic (HL-60) cells.
    Sweet S; Singh G
    J Cell Physiol; 1999 Jul; 180(1):91-6. PubMed ID: 10362021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.